Amanda Myers, MD, of the University of Texas MD Anderson Cancer Center, highlights her recent study that challenges the current paradigm of discouraging additional BCG therapy for patients classified as having “BCG-unresponsive” non-muscle invasive bladder cancer.
Dr. Myers presented her results at the 2024 European Association of Urology Congress.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.